TradersLink News
Small Cap News Context
Saved TradersLink press-release and filing article pages. Discord alerts can link here when full article context is available.
Published Articles
Latest saved alerts
WPP CEO Cindy Rose: 88,188 RSUs vested; 41,532 shares sold at GBP 3.692
WPP filed SEC Form 4. Rose reported RSUs vesting on Sept 1, 2026 that resulted in acquisition of 88,188 ordinary shares and a contemporaneous disposition of 41,532 shares at GBP 3.692 per share (~USD 4.97), leaving her with 346,950 directly beneficially owned ordinary shares. The Form 4 (filed Sept 2, 2026) also shows 3,409,211 derivative securities beneficially owned following the transaction (listed under a 'CEO buyout award').
LHSW prices $11.0M follow-on: 7.64M units at $1.44; 3 warrants/unit (6‑mo, $1.66)
Lianhe Sowell (LHSW) priced a best-efforts follow-on of 7,638,889 units at $1.44 per unit for gross proceeds of $11.0M; each unit contains one Class A ordinary share and three warrants (6‑month term, $1.66 exercise) and the shares and warrants are immediately separable and will be issued separately. The offering is expected to close on or about Sept 3, 2026 with R.F. Lafferty as sole placement agent, so initial share issuance/dilution will occur at closing while additional dilution could occur if warrants are exercised within the six-month exercise window. Timing: The press release does not indicate dilution today; initial share dilution occurs at the offering close (Sep 3, 2026), and once the offering closes those shares have been issued.
Borealis (BRLS) notified by Nasdaq for late Q2 2026 10-Q; given Oct 26 to submit compliance plan
Borealis Foods (NASDAQ: BRLS) said it received a Nasdaq notice of noncompliance for failing to timely file its Form 10-Q for the quarter ended June 30, 2026, but trading of its shares and warrants is not immediately affected. The company has until Oct 26 to submit a compliance plan (Nasdaq may allow up to Feb 16, 2027 to regain compliance) and says the delay is due to an auditor review of the proper accounting treatment for a previously disclosed Conversion Agreement that may require shareholder approval; it intends to file promptly after completing that review.
RITR’s Jingxing HK enters delivery on two Cainiao Europe warehouses; $30M North America cold‑storage deal to start
Jingxing HK (Reitar/NASDAQ: RITR) and Cainiao have moved their cooperation into the delivery phase for two large automated warehouse projects in Spain and the Netherlands, with racking supply and engineering underway, racking delivery expected by end-September 2026 and installation targeted by year-end. Jingxing HK and Shanghai Jingxing also have an approximately US$30 million automated cold‑storage project in North America expected to commence in September 2026; the work integrates Cainiao’s climbing-robot automation with Jingxing’s racking and aims to open further European and international e‑commerce warehouse opportunities.
LiveOne to distribute Bare Knuckle Ice Wars PPV via PPVOne after ESPN debut
LiveOne (LVO) is expanding its PPVOne partnership to distribute Bare Knuckle Ice Wars’ Sept. 5 championship card live on pay-per-view, featuring UFC Hall of Famer Tito Ortiz and three title fights on a sold-out card. Ice Wars arrives with recent momentum — a national ESPN debut, >15 million social views and BKFC ownership links — and PPVOne has historically generated more than $30M in revenue and ~$5M in EBITDA across 250+ livestreams and 200+ countries.
LiveOne to distribute Bare Knuckle Ice Wars PPV via PPVOne after ESPN debut
LiveOne (LVO) is expanding its PPVOne partnership to distribute Bare Knuckle Ice Wars’ Sept. 5 championship card live on pay-per-view, featuring UFC Hall of Famer Tito Ortiz and three title fights on a sold-out card. Ice Wars arrives with recent momentum — a national ESPN debut, >15 million social views and BKFC ownership links — and PPVOne has historically generated more than $30M in revenue and ~$5M in EBITDA across 250+ livestreams and 200+ countries.
Class action alleges Innventure misled investors about Accelsius/DarkNX deal; shares plunged 55%
A class action complaint was filed against Innventure (INV) covering Nov 17, 2025–Aug 13, 2026 alleging the company misled investors about a purported Accelsius deal with DarkNX and overstated 2026 revenue and cash flow targets. Innventure disclosed on Aug 13 that the DarkNX deployment site was no longer available and removed the project from Accelsius’ internal bookings, and the stock fell $1.98 (55%) the next day; deadline to seek lead plaintiff status is Oct 27, 2026.
VTIX to Demo AI Counter-Drone Training System to U.S. Army at Maneuver Warfighter Conference
Virtuix (VTIX) will showcase its AI-enabled Counter-Unmanned Aircraft System (C-UAS) Personnel Trainer, built with LeadTech and integrating the Omni One omni-directional treadmill, to U.S. Army and Joint leaders at the Maneuver Warfighter Conference Sept. 15-17. The simulator uses full-body movement and digital-twin ranges for realistic counter-drone marksmanship training and the company says the system is under evaluation by USMC TECOM and supported by recent AFWERX SBIR Phase I funding and other programs across all four U.S. military branches, though no procurement dollars or firm contracts were disclosed.
GCTK: Lōkahi partners with SDSU to expand ai² Futures Lab asset sourcing
Glucotrack-operated Lōkahi Therapeutics (GCTK) announced a collaboration with San Diego State University's Fowler College of Business to expand its ai² Futures Lab network for identifying and evaluating overlooked or deprioritized therapeutic assets. In year one the program engaged 64 students and identified more than 45 potential assets, several of which advanced into active pipeline discussions, and Lōkahi says the partnership is intended to boost its sourcing and analytical capacity for capital-efficient pipeline development.
Offerpad CEO Brian Bair wins HousingWire 2026 Vanguard award; company notes 85k+ transactions
Offerpad (OPAD) said founder, chairman and CEO Brian Bair was named a 2026 HousingWire Vanguard Award winner for his leadership and innovation in residential real estate. The company highlighted operational scale (over 85,000 transactions and 39,000 homes purchased, renovated and resold as of June 30, 2026) and reiterated its multi-product platform and investments in data/AI—this is a credibility/branding announcement rather than a material financial update.
Silver in sixth straight deficit; capital returning to Cobalt‑Gowganda district
AI summary could not be provided for this article.
Advasa adds USDC payments to ADVASA Visa card, will explore RWA tokenization
Advasa added USD Coin (USDC) payment functionality to its ADVASA Visa card so users can pay with USDC alongside fiat through its FUKUPE earned-wage-access (EWA) platform, which disburses wages to bank accounts, prepaid cards and digital wallets. The company also said it will explore opportunities in real-world asset (RWA) tokenization as a potential extension of its payments infrastructure, citing a projected $18.9T tokenization market by 2033.
CANF: Warrants exercised for ~$4.0M at $2.50; new warrants for 3.18M ADSs issued
Can‑Fite agreed to immediate cash exercise of up to 1,591,738 outstanding warrants at a reduced $2.50 per ADS (down from $5.00), generating approximately $4.0M gross, with closing expected on or about 2026-09-03. In the transaction the company will issue new unregistered warrants to purchase up to 3,183,476 ADSs at $2.50 (immediately exercisable for up to 24 months); the ADSs issuable on exercise are registered on an effective Form F-3 and H.C. Wainwright is exclusive placement agent. Timing: Warrant exercises are already completed, so dilution is already in effect.
Genasys wins orders for Protect and Evertel deployments in 14 U.S. states
Genasys (GNSS) said law enforcement and public safety agencies in 14 states ordered its Genasys Protect or Genasys Evertel software this summer, with deployments now underway across city, county, federal, university and tribal agencies. The company said the wins include new and follow-on orders and that a growing pipeline contains potential large software opportunities to extend coverage, but the release discloses no contract values, revenue impact, or timing.
Dolphin's The Digital Dept hosts private 'Ranch House' for creators at LTK Con 2026
AI summary could not be provided for this article.
SMSI's SafePath OS debuts on Consumer Cellular's SpeakEasy senior phones
Consumer Cellular launched a connected-care solution for older adults built on Smith Micro's SafePath OS for Senior Phone, available on SpeakEasy smartphone and flip devices and sold through the SpeakEasy Connect Care+ plan with a caregiver app on iOS and Android. The launch is the first commercial deployment of SafePath OS for Senior Phone and expands Smith Micro's distribution into Consumer Cellular's senior-focused customer base, though the release discloses no financial terms or expected revenue impact.
Class action filed against Blaize (BZAI); lead-plaintiff deadline Oct 5, 2026
A class action was filed alleging Blaize (NASDAQ: BZAI) made false/misleading statements, entered transactions with entities unable to conduct meaningful business, and improperly recognized revenue; the complaint says a Pelican Way Research report on April 28, 2026 revealed the issues and the stock fell ~12% that day. Investors who bought shares between July 18, 2025 and April 28, 2026 may move the court to be lead plaintiff by Oct 5, 2026.
AIM wins European & UK patents for Ampligen in Long COVID through 2041
AIM ImmunoTech announced patents in multiple European countries and the U.K. covering use of Ampligen (tdsRNA) to treat Long COVID, with protection expected through June 2041 after the nine‑month opposition period closed with no challenges; claims include specific dosing regimens and intranasal, intravenous and inhalation delivery. The company says the grants expand its global Ampligen IP estate and complement a recently issued U.S. patent for Ampligen+pembrolizumab, and cites >1,200 patients and 100,000+ doses of clinical experience with favorable safety.
MBody AI Orchestrator shortlisted for AI Deployment of the Year
MBody AI (NASDAQ: MBAI) said its MBody AI Orchestrator platform was shortlisted as a finalist for "AI Deployment of the Year" in The 2026 A.I. Awards, alongside CrowdStrike, Lenovo, CVS Health and Lloyds Banking Group. Orchestrator is a hardware-agnostic fleet-management embodied-AI platform running in production with Fortune 500 casino and resort operators (cumulatively servicing ~600 million sq ft), and the company says operational telemetry from those deployments is used to refine its models over time.
Definitive Healthcare names Clay Ritchey as CEO, effective Sept. 8, 2026
Definitive Healthcare (NASDAQ: DH) appointed Clay Ritchey as CEO effective Sept. 8, 2026, replacing Kevin Coop who departed Aug. 31, 2026. Ritchey — a 25+ year healthcare data executive who most recently led Verato and previously ran Evariant — said he'll push to accelerate a return to growth and roll out an AI-powered platform that pairs the company's proprietary datasets with conversational AI and workflows.
Envoy Medical (COCH) to present at H.C. Wainwright conference on Sept. 15
Envoy Medical (COCH) said CEO Brent Lucas will present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 15 at 2:00 PM ET; the presentation will be webcast and available on demand for 90 days. The company highlights its innovation pipeline in the release — including the investigational Acclaim fully implanted cochlear implant (FDA Breakthrough Device) and the commercial Esteem implant — so the session is a likely venue for pipeline, clinical or regulatory updates.
VERU CEO to speak at Cantor Healthcare conference; PLATEAU Phase 2b fully enrolled
Veru said CEO Mitchell Steiner will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Sept. 9 (webcast available). The company also reported the PLATEAU Phase 2b trial of enobosarm plus semaglutide is fully enrolled at 239 patients (vs a 200 patient target), with a DXA-based interim analysis due in Q1 2027 and final topline data expected in Q4 2027.
Vivakor guides Q3 2026 supply & trading revenue at ~$270M
Vivakor provided preliminary guidance that Q3 2026 supply & trading revenue will be about $270 million. The CEO said the figure is meant to give investors clarity as the company's commercial activity expands, but no additional financial details or supporting metrics were disclosed.
Orion (OESX) to present at H.C. Wainwright conference Sept 14-16
Orion Energy Systems (OESX) said CEO Sally Washlow will deliver a company presentation and be available for one-on-one investor meetings at the 28th Annual H.C. Wainwright Global Investment Conference Sept 14-16; a webcast link will be posted to the investor events page when ready. Management access at the conference gives investors a chance to get direct updates on Orion’s LED lighting, EV charging and maintenance services businesses.
SciSparc unit pursues FDA orphan status for Tourette drug, hires RK Strategies
SciSparc's majority-owned NeuroThera is pursuing FDA Orphan Drug Designation for SCI-110 (adult Tourette syndrome) and has retained RK Strategies to support U.S. government and public affairs engagement. SCI-110 is a cannabinoid-based combo now in a Phase IIb program at Yale, Hannover and Tel Aviv after a Phase IIa that showed an average 21% tic reduction, so orphan status could boost regulatory/commercial profile but clinical benefit remains preliminary.
Securities suit alleges Alarum subsidiary NetNut linked customers' home devices without consent; lead-plaintiff deadline Oct 5, 2026
Kaplan Fox filed a securities class action on behalf of investors who bought Alarum Technologies (NASDAQ: ALAR) between March 20, 2025 and July 2, 2026, alleging an Alarum subsidiary, NetNut, illegally linked customers' home internet devices into other networks without consent and that this activity allowed cyber criminals to conceal locations. The complaint says those practices materially heightened Alarum's legal exposure and threatened its business prospects; investors seeking lead-plaintiff status must move the court by October 5, 2026.
IVDA's IvedaAir draws defense and Fortune 500 interest, schedules fall flight demo
Iveda (IVDA) says it has received inbound interest from Fortune 500 defense and aerospace contractors, government agencies, and major commercial organizations for its newly launched IvedaAir rotary-wing RUAS. The company is hosting an invitation-only flight demonstration in Arizona this fall to push evaluations toward pilots and procurement; the gas-powered GX10-F100 platform claims >150 minutes endurance, integrates with IvedaAI, and is NDAA/TAA compliant and available for government purchase via partner GlobalMed under a DLA contract vehicle.
BODi launches 9-week MAX BUILT strength program from Shaun T
BODi launched MAX BUILT, a nine-week progressive-overload strength program by Shaun T, featuring a simple five-move format, a three-phase progression, and workouts that take 30–40 minutes and require only dumbbells and an adjustable bench. The program is exclusive to the BODi platform and is positioned to meet rising consumer demand for at-home strength training while being promoted alongside BODi’s Shakeology and P90X supplement lineup. No pricing, early adoption metrics, or subscriber guidance were provided, leaving impact on subscriptions and revenue unclear.
Google signs offtake for MN8 solar project using Eos Z3 long‑duration storage in West Virginia
MN8, Google and Eos announced the Mammoth Solar project in West Virginia combining 86 MW of utility-scale solar, 70 MW/280 MWh of lithium-ion storage and a 10 MW/100 MWh Eos Z3 zinc-based long-duration storage system; Google will purchase the energy, capacity and clean attributes. The solar is expected online in 2028 with lithium storage in 2029 and the Eos LDES in 2030 — the deal is the first commercial-scale LDES deployment in West Virginia and is pitched to deliver dispatchable, around-the-clock capacity to the PJM grid and Google’s data centers, with MN8 estimating up to $350M capex and ~200 construction jobs.
High Roller (ROLR) sets invitation-only ROLR beta for Sept 15; public launch targeted by end of Oct
High Roller Technologies (NYSE: ROLR) said its ROLR prediction-markets platform will start an invitation-only closed beta on Sept 15, 2026, with a public commercial launch targeted by the end of October 2026. The closed beta will run live, controlled tests of onboarding, ID/geolocation, deposits/withdrawals, order execution and contract settlement to validate platform stability, scalability and operational readiness before broader rollout.
3 E Network (MASK) to sell 701,272 shares in $1.0M CEO-led private placement at $1.42598
3 E Network agreed to a $1.0M private placement of 701,272 Class A ordinary shares to a Singapore entity controlled by CEO Dr. Tingjun Yang at $1.42598 per share. Closing is subject to customary conditions and will occur on a mutually agreed date (so dilution is delayed until closing); the shares will be issued in an unregistered Rule 506(b) placement, the audit committee and Board approved the related‑party deal, and no placement agent or fees were engaged. Timing: Same-day dilution is possible, but the press release does not provide a firm first-dilution date.
cbdMD agrees to acquire Twinlab brands (Twinlab, Reserveage, Metabolife) via ABC proceeding
YCBD filed SEC Form 8-K. CbdMD entered a definitive asset purchase agreement to acquire operating assets and brands of Twinlab (including Twinlab, Reserveage, Metabolife and Alvita Tea) through an assignment for the benefit of creditors (ABC), subject to court approval and customary closing conditions. Based on unaudited trailing twelve months revenue through June 2026, the combined business would total approximately $30 million (about a 40% increase vs. cbdMD standalone TTM), and cbdMD expects the incremental revenue to generate positive contribution after transaction and integration costs.
KIDZ AI to buy 2% stake in Cambodia's national Tier III data center, secures priority access to up to 1 MW
KIDZ AI agreed to acquire a 2.0% minority interest in HUADING DEVELOPMENT (CAMBODIA) Co., making it a strategic equity partner in Cambodia's operational, government-designated Tier III national cloud data center and obtaining a three-year right of first refusal to lease up to 1 MW (drawable in tranches) plus a 30-day exclusive right of first offer on future expansions. The facility is energized, carrier-neutral, connected to multiple international submarine cables, and offers immediate power- and network-connected capacity for AI/GPU workloads—accelerating KIDZ AI's entry into Southeast Asian AI infrastructure versus building new capacity. The transaction is subject to customary closing conditions, due diligence and regulatory approvals, so completion and exercise of capacity rights are not guaranteed.
Polyrizon completes contracts at all 5 U.S. sites for NASARIX first-in-human allergy trial
Polyrizon (PLRZ) said it has executed contracts with all five U.S. clinical sites for its first-in-human NASARIX (PL-14) allergy blocker study and is moving the program into study execution, including patient pre-screening and enrollment preparations. The prospective, multicenter, randomized single-blind trial plans to enroll up to 120 patients randomized 1:1 to NASARIX vs isotonic saline, with the primary endpoint of mean daily reflective Total Nasal Symptom Score (rTNSS) over the first 14 days and safety/secondary endpoints defined; enrollment will be timed to local allergy seasons.
Real-world data: CytoSorb cuts severe bleeding in CABG patients on ticagrelor; FDA pre-sub meetings advance DrugSorb‑ATR plans
CytoSorbents (CTSO) reported a patient-level matched real-world analysis of 587 urgent CABG patients on ticagrelor showing intraoperative CytoSorb use was associated with a 37% relative reduction in severe perioperative bleeding (BARC‑4: 21.8% vs 34.5%) and an NNT of 8, plus reductions in 24‑hr chest tube drainage and RBC transfusions with no serious device‑related adverse events. The company said the data—presented at ESC 2026—will be a core component of an expanded De Novo submission for DrugSorb‑ATR under FDA Breakthrough designation and that recent FDA pre-submission meetings were constructive for parallel ticagrelor and DOAC applications, with a planned new De Novo submission in early 2027.
Edible Garden regains Nasdaq $1.00 bid-price compliance; one-year monitor imposed
Edible Garden (NASDAQ: EDBL, EDBLW) said Nasdaq has confirmed the company has regained compliance with the $1.00 minimum closing bid requirement following a July 27 panel decision to grant continued listing. Nasdaq placed a Mandatory Panel Monitor on the company for one year from Aug 31, 2026 and the Panel retains jurisdiction through Nov 23, 2026, meaning another bid-price lapse during the monitor would prompt a delisting determination without an additional cure period.
OSTX: OST‑HER2 showed positive Phase 2b results; FDA/MHRA/EMA meetings set and BLA/CMAA filings targeted Q4 2026
OS Therapies says OST‑HER2's Phase 2b reported a clinically significant benefit on the 12‑month event‑free survival primary endpoint and an overall survival secondary endpoint, and it plans regulatory interactions (FDA Type C statistical meeting mid‑Sept 2026 plus MHRA/EMA meetings) before seeking Accelerated Approval BLA and Conditional Marketing Authorisation submissions in Q4 2026. The company expects RMAT/rolling review decisions to follow the FDA meeting, aims to file under accelerated/conditional pathways (with potential Priority Review Voucher eligibility if a U.S. BLA is granted), and plans a confirmatory Phase 3 CTA and final 3‑year OS data also in Q4 2026.
Cardiff Oncology (CRDF) to Present at Sept 2026 RAS Summit and H.C. Wainwright Conference
Cardiff Oncology (NASDAQ: CRDF) said Mani Mohindru, Ph.D. will present on Sept. 8 at the 8th Annual RAS-Targeted Drug Development Summit and participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Sept. 14; slides and a webcast replay will be available on the company website. Management will use these events to discuss onvansertib, the company’s oral PLK1 inhibitor currently in a Phase 2 trial for first-line RAS‑mutated metastatic colorectal cancer, which could increase investor visibility ahead of any clinical updates.
Robo.ai (AIIO) reports >$180M revenue for June–Aug, driven by QC Capital deal
Robo.ai (Nasdaq: AIIO) said it recorded more than US$180 million of revenue for June–August 2026, primarily driven by the June 15 acquisition of Quantum Core Capital (QC Capital). The company said the acquired business has continued to contribute meaningfully as integration proceeds, but the revenue figures are preliminary and unaudited. Consideration shares for the QC Capital deal are subject to a phased, revenue‑linked release mechanism, which could trigger contingent share releases tied to revenue performance.
CDT: Shares outstanding 13,693,866 after recent issuances; Nasdaq deficiencies cleared
CDT Equity says recent share issuances and exercises of pre-funded warrants resulted in 13,693,866 shares outstanding as of August 31, 2026, and that it no longer has any Nasdaq listing deficiencies. The release does not disclose offering size, pricing, placement agents, or gross proceeds, so the exact cash raised and incremental dilution versus the prior cap table are not specified. Timing: Same-day dilution is possible, but the press release does not provide a firm first-dilution date.
Argo Graphene names battery expert Dr. Said Al‑Hallaj to board
Argo Graphene (CSE: ARGO; OTCQB: ARLSF; FSE: 94Y) appointed Dr. Said Al‑Hallaj, a 25+ year battery and energy‑storage scientist and current Chief Battery Scientist at Beam Global (BEEM), to its board to help advance commercialization of its STREAM graphene production technology. His prior work with Grapherry and experience in batteries, thermal management and technology commercialization positions Argo to prioritize energy‑storage and electronics applications, though the company did not announce technical validation, pilots, customers or timelines tied to the hire.
HWH leadership change — Chan to step down; Liu Ming Hui named Executive Chairman, Dr. Liu Ming Xing named CEO
HWH International (HWH) announced that Chairman & CEO Chan Heng Fai will step down from both roles effective Sept. 1, 2026, remaining on the board as a director. He will be succeeded by Liu Ming Hui as Executive Chairman and Dr. Liu Ming Xing as CEO; the incoming leadership pair bring deep China Gas leadership and policy experience, including having scaled China Gas Holdings into a major cross-regional gas and clean-energy operator.
S-1/A registers common stock, pre-funded warrants, warrants and convertible instruments — potential resale overhang
CYAB filed SEC Form S-1/A. The filing references underwriters (Ladenburg, LifeSci), PIPE/convertible notes, promissory notes and conversion agreements that can increase share supply on conversion or exercise, but the supplied text does not include offering size, price, share counts, effectiveness status or lock-up timing.
aTyr expects mid-September FDA reply on Phase 3 protocol for efzofitimod in pulmonary sarcoidosis
ATyr (ATYR) says it anticipates an FDA response by mid-September 2026 to the protocol submitted in June for a planned Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The proposed global, randomized, double-blind, placebo-controlled 54-week trial would enroll up to ~372 patients, randomize 1:1 to 5.0 mg/kg IV efzofitimod or placebo every 3 weeks (17 doses), and use change in FVC at week 48 as the primary endpoint with King's Sarcoidosis Questionnaire‑Lung score as a key secondary.
bioAffinity says CyPath Lung being advanced for post-treatment surveillance of lung cancer survivors
BIAF filed SEC Form 8-K. The release cites three years of commercial use and published detection‑setting performance (92% sensitivity, 87% specificity, 88% accuracy, 99% NPV for nodules <20 mm) and notes the test is marketed as a CLIA Laboratory Developed Test via a subsidiary. The company explicitly states those performance data apply to detection and have not been validated for post‑treatment surveillance and warns of regulatory, clinical‑data and business risks including oversight of LDTs and its limited operating history.
LGL completes redomestication to Nevada; listing and shares unchanged
LGL Group (NYSE: LGL) completed its redomestication from Delaware to Nevada effective Sept. 1, 2026, adopting new Nevada articles and bylaws and converting each outstanding common share one-for-one with no shareholder action required. Trading will continue on the NYSE American under ticker LGL and the company says the move does not change its business, operations, management, assets or workforce aside from costs related to the redomestication.
XOS Hub Hits >1 GWh Delivered in Field; wins Xcel follow-on order and US Air Force prototype
Xos says a single Xos Hub has exceeded 1,020,143.6 kWh (~1 GWh) of cumulative energy delivered in real-world service since early 2025, averaging ~1,800–2,000 kWh/day across more than 33,600 charging sessions; its connected fleet has delivered >5 GWh to date. The company frames the milestone as field-proof of durability that supports higher-capacity Hub tiers (up to 630 kWh), a new megawatt-scale Power Hub, UL-2202 certification, and recent commercial orders from Xcel Energy plus a U.S. Air Force prototype OTA, though no contract values or near-term revenue impact were disclosed.
Hyperscale Data says blockchain-related Other Revenue rose 647% in Q2, boosting gross profit
Hyperscale Data (GPUS) reported that Other Revenue, driven largely by its blockchain initiatives, increased 647% year-over-year to ~$3.4M in Q2 2026, contributing to consolidated revenue of $34.8M (+35% YOY) and gross profit of $8.8M (+44% YOY). The company notes blockchain revenue is reported inside the Other Revenue line (not broken out), the Ault Blockchain mainnet launched in March 2026, and additional products (exchange, tokenization, payments, lending) are being developed but remain subject to technical, market and regulatory risks.
Global Self Storage (SELF) declares $0.0725 Q3 2026 cash dividend
Global Self Storage (NASDAQ: SELF) declared a cash dividend of $0.0725 per common share for Q3 2026, payable Sept. 30, 2026 to shareholders of record on Sept. 16, 2026. Management says it will continue funding acquisitions and expansion projects and the board is regularly reviewing capital allocation, but notes dividends and forward-looking plans are subject to change and other risks.
WALD director's fund buys 335,000 Class A shares at $1.5094
WALD filed SEC Form 4. After the transaction the fund beneficially owned 12,587,580 shares (indirect); Souza states he is the controlling shareholder of the fund's manager and disclaims direct beneficial ownership except for pecuniary interest.
Ticker Pages